



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁴ : A61K 39/00, 45/05, 39/40	A1	(11) International Publication Number: WO 89/ 01338 (43) International Publication Date: 23 February 1989 (23.02.89)
(21) International Application Number: PCT/US88/02822 (22) International Filing Date: 17 August 1988 (17.08.88) (31) Priority Application Number: 086,372 (32) Priority Date: 17 August 1987 (17.08.87) (33) Priority Country: US (71)(72) Applicant and Inventor: MCMICHAEL, John [US/ US]; Westfall & Larry Hill Road, R.D. 1 (P.O. Box 127), Delanson, NY 12053 (US). (74) Agent: MEINERT, M., C.; Marshall, O'Toole, Gers- tein, Murray & Bicknell, Two First National Plaza, Ste. 2100, Chicago, IL 60603 (US).		(81) Designated States: AT (European patent), BE (Euro- pean patent), CH (European patent), DE (European patent), FR (European patent), GB (European pa- tent), IT (European patent), JP, LU (European pa- tent), NL (European patent), SE (European patent). Published <i>With international search report.</i>
(54) Title: IMMUNOTHERAPEUTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES OF VIRAL ORIGIN, INCLUDING ACQUIRED IMMUNE DEFICIENCY SYNDROME		
(57) Abstract Methods and compositions useful for treating acquired immune deficiency syndrome by once daily administration of substances characteristic of acquired immune deficiency syndrome-afflicted cell (such as human chorionic gonadotropin), and effective fragments and derivatives thereof, in a pharmaceutically effective amount less than the lowest amount necessary to provoke a humoral immune response, as exemplified by the existence of a negative wheal upon subcutaneous administration. Illustrative of such methods and compositions is the administration of a composition including human chorionic gonadotropin (HCG), a lysate of <i>Staphylococcus aureus</i> , influenza virus vaccine, and fractionated HIV virus, including peptide T.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

- 1 -

"Immunotherapeutic Methods and Compositions for the Treatment of Diseases of Viral Origin, Including Acquired Immune Deficiency Syndrome"

CROSS-REFERENCE TO RELATED APPLICATIONS

5 The present invention is a continuation-in-part of co-pending U.S. Patent Application Serial No. 692,822, filed January 18, 1985.

BACKGROUND OF THE INVENTION

10 The present invention pertains in general to immunotherapeutic techniques for treating diseases of viral origin. In particular, the present invention pertains to immunotherapeutic techniques useful in
15 treatment of disease states such as feline leukemia, bovine leukemia, acquired immune deficiency syndrome (AIDS), and acquired immune deficiency syndrome related complex (ARC).

20 In order to protect the integrity of the organism, higher vertebrates possess an elaborate immune system which distinguishes foreign substances, which must provoke an immune response in order to be eliminated, from "self" substances, which are tolerated. The mechanism that effectuates this
25 discrimination between self and foreign substances is known to involve interactions among types of white blood cells (leukocytes).

30 Upon exposure to the circulating fluids of the body, substances capable of recognition by the immune system (antigens) come into contact with a type of leukocyte called a macrophage. Macrophages are phagocytic cells and can therefore engulf and destroy those materials which are not protected from them by size, surface texture (i.e., smoothness), surface
35 charge, or some other mechanism.

- 2 -

Once engulfed and processed by a macrophage, an antigen or a portion thereof is presented at the surface of the macrophage for contact with another type of leukocyte called a thymocyte or T-cell. T-cells control the production of antibodies by yet another type of lymphocyte called a B-cell.

Antibodies are B-cell-produced proteins which are capable of combining with an antigen in a reaction which is specific for that antigen. An antibody only combines with certain portions (antigenic determinants) of the surface of the antigen, so that the antibody is specific to the degree that the determinant with which it combines is not also found on other antigens.

The binding of an antibody to its corresponding antigen on the surface of a foreign cell has significant consequences related to the destruction of that cell by the immune system. First, the coating of the cell by antibody facilitates ingestion of the cell by macrophages and by other types of phagocytes including killer (K) cells, which act to destroy antibody-coated cells but which do not require sensitization by prior exposure with macrophage-processed antigen, and polymorphonuclear (PMN) leukocytes. Second, the coating of a cell by antibody activates a system of proteins, known as the complement system, in the liquid (plasma) fraction of the blood. Upon activation of this system, complement components also coat the foreign cell, which facilitates phagocytosis. In addition, complement activation results in the stimulation of inflammatory cells, leading to production of chemicals which attract macrophages through a process called chemotaxis and leading to inflammatory hormone-like activation of cellular functions. Lastly, complement components act

35

- 3 -

directly to break up (lyse) the membrane of the foreign cell. The portion of the immune response involved with antigen-antibody and complement interactions is generally referred to as the humoral reaction.

5 T-cells, which regulate the humoral reaction, are of several types. These types of T-cells have been described as including helper (T_H) cells, inducer (T_I) cells, regulator (T_R) cells, and suppressor (T_S) cells. Herscovitz, Chapter 7 in Immunology III,
10 Bellanti, J.W. Saunders, Philadelphia (1985). T_I and T_H cells are mobilized by contact with processed antigen on the surface of macrophages. T_H cells are also activated by signals from T_I and from T_R cells. T_R cells are activated by signals from T_I and T_S cells. Mobilization
15 of T_S cells occurs in response to signals from T_R cells or as a result of contact with antigen.

Introduction of an optimal amount of a foreign substance into the fluids of the body initiates a process which results in production of antibody by B-cells. In this process, B-cells respond to stimulation
20 by T_H cells, which have in turn been stimulated by macrophages. Introduction of a persistent low level of some antigens or of a high level of an antigen results in a low-level of or in a lack of production of antibody
25 due to an interruption by T_S cells of the signals from T_H cells to B-cells. This interruption, called suppression, may be induced through the macrophage- T_I - T_R pathway or by direct stimulation of the T_S cells by antigen. Suppression of antibody production to a first
30 antigen may be overcome in a process known as contrasuppression through the stimulation of a subtype of T_S cells called contrasuppressor cells by a second antigen which is antigenically similar to the first antigen. These contrasuppressor cells send a signal to
35 T_R cells which render the T_H cells resistant to the activity of the suppressor T_S cells and which interrupt

- 4 -

the suppressor signals of the suppressor T_S cells. See Gershon, et al., J.Exp.Med., 153:1533-1546 (1981); Yamauchi, et al., J.Exp.Med., 153:1547-1561 (1981); and Green, et al., Ann.Rev. Immunol., 1:439-463 (1983).

5 It is the balance of the actions of T_H helper and T_S suppressor cells which determines whether an immune response develops in the presence of an antigen. Thus, as a practical matter, the functioning of the network of T-cells may be viewed in terms of the
10 ratio of helper to suppressor cells (T_H/T_S).

T-cells are also involved in another type of immune response which is said to involve cell-mediated immune (CMI) reactions. Contact of T_H cells with macrophage-processed antigen causes the T_H cells to release
15 interleukin II (IL-2), which activates cytotoxic (T_{CYT}) T-cells and, in conjunction with gamma interferon also released by the T_H cells at this time, activates natural killer (NK) cells. Both T_{CYT} and NK cells kill foreign cells. T_{CYT} cells are particularly involved with
20 rejection and with the destruction of tumor cells.

As is evident from the foregoing discussion, a general outline of the functioning of the immune system is available. However, many areas of the functioning of the immune system remain unclear. One of these areas
25 relates to the apparent inability of the immune system to recognize certain cancers (malignant neoplasms) and cells infected with certain viruses, e.g., feline leukemia virus; bovine leukemia virus; and human T-leukemia-lymphoma virus (HTLV), which is believed to be
30 the causative agent in AIDS.

In attempts to stimulate an immune response against a malignant neoplasm, many approaches have been aimed at the augmentation of antitumor defenses by administration of adjuvants (immune enhancers or
35 potentiators). These approaches attempt to enhance nonspecific phagocytosis and killing of tumor cells by

- 5 -

macrophages and T-cells. Such approaches employ infectious BCG mycobacteria, non-living Corynebacterium parvum, glucan (a glucose polymer derived from microorganisms), or levamisole (an antihelminthic drug known to be useful for stimulating CMI and the action of macrophages). Herberman, et al., Chapter 19 in Immunology III (Bellanti, ed.), W.B. Saunders Co. (1985), at page 343. The reported antitumor action of lysosome and pepsin lysates containing glycopeptides from the cell wall of Lactobacillus bulgaricus [Bogdanov, et al., FEBS Letters, 57:259 (1975); Bogdanov, et al., Byulletin Eksperimental'noi Biologia i Meditsiny, 84:709 (1977)] and the treatment of malignant tumors with destroyed Staphylococcus aureus [abstract of examined Japanese Patent Application No. 84 046487] appear also to fall in this category. Adjuvant therapy has had varying degrees of questionable or limited success. Herberman, et al., supra.

The failure of the immune system to recognize malignant neoplasms is particularly puzzling in view of the fact that certain characteristic substances (tumor markers) are present at levels which are elevated above normal in patients with various neoplastic disease states. Specifically, alphafetoprotein (AFP), carcinoembryonic antigen (CEA), and human chorionic gonadotropin (HCG) are oncofetal tumor markers widely used in the investigation of patients with neoplasms of the liver, colon, and trophoblast, respectively. AFP has been found at levels elevated above normal in fifty percent or more of patients with yolk sac tumors, hepatomas, retinoblastomas, embryonal carcinomas, breast carcinomas, and carcinomas of the uterine cervix, and has been found at elevated levels in between two and fifty percent of patients having carcinomas of the pancreas, melanomas, gastric carcinomas, basal cell carcinomas, bronchogenic carcinomas, pancreatic

- 6 -

carcinomas, medullary thyroid carcinomas, familial medullary thyroid carcinomas, osteosarcomas, retinoblastomas, ovarian cystadeno-carcinomas, mycosis fungoides, hepatomas, esophageal carcinomas, adenocarcinomas of the uterine cervix, lung carcinomas, carcinomas of the small intestine, urinary bladder carcinomas, and renal cell carcinomas, and has been found at elevated levels in between nine and fifty percent of patients having neural crest tumors, breast carcinomas, prostatic carcinomas, primary uveal carcinomas, neuroblastomas, fluids with malignancy, seminomas, basal cell carcinomas, gastric carcinomas, laryngeal carcinomas, endometrial carcinomas, uterine cervix intraepithelial carcinomas, carcinomas of the buccal mucosa, craniopharyngiomas, embryonal rhabdomyosarcomas, carcinomas of the oropharynx, brain tumors and testicular teratomas. HCG has been found at elevated levels in the serum of fifty percent or more of patients having choriocarcinomas, malignant interstitial cell tumors of the testis, non seminomatous tumors of the testes, embryonal carcinomas, and pancreatic carcinomas, and has been found at elevated levels in between six and fifty percent of the patients having teratomas, ovarian adenocarcinomas, uterine cervix carcinomas, endometrial carcinomas, seminomas, gastric carcinomas, urinary bladder carcinomas, breast carcinomas, colorectal carcinomas, bronchogenic squamous cell carcinomas, melanomas, and multiple myelomas. Other universal oncofetal tumor markers, including tissue polypeptide antigen (TPA), which is associated with cell proliferation and which is not specific for any species, are also known. See, Klavins, Annals of Clinical and Laboratory Science, 13:275-280 (1983).

With respect to HCG, a chorionic gonadotropin-like antigen has been found in bacteria isolated from the urine of cancer patients, as indicated in Acevedo,

- 7 -

et al., Infection and Immunity, 31:487-494 (1981), but not in the same species of bacteria obtained from any other source tested. Furthermore, rat mammary adenocarcinoma cells and rat hepatoma cells have been found to synthesize chorionic gonadotropin-like material, although no such material was found in the sera of the animals bearing these neoplasms, in Kellen, et al., Cancer Immunol. Immunother., 13:2-4 (1982). In the papers of Kelle, et al., and in U.S. Patent No. 4,384,995, a subunit of HCG conjugated to tetanus toxoid is used to prophylactically stimulate an immune response to chorionic gonadotropin-like substances by repeated injection with the conjugated material before exposure to tumor cells known to bear a chorionic gonadotropin-like antigen.

Among the differences between prophylactic treatment with HCG and the adjuvant therapy approach is that the induction of an immune response for prophylactic purposes requires repeated injections over a period of time in order to initiate the development of at least one population of identical B-cells (a clone) producing a given antibody to a tumor antigen and for antibody to be produced by that clone. On the other hand, adjuvant therapy may result in antibody production by an existing clone of B-cells and thus has antitumor effects which may be immediately observed. Therapeutic treatment (i.e., treatment after a malignant neoplasm is present) with HCG conjugated with tetanus toxoid raises the possibility of an uncontrollable Herxheimer-type reaction. The Herxheimer reaction appears after treatment of syphilis patients with a substance that is toxic to the causative spirochete bacteria, which bacteria thereupon die in massive numbers, releasing potentially fatal toxic substances from the bacteria

- 8 -

into the blood stream. By analogy, at some as yet unpredictable point in the induction of an immune response to a tumor antigen, a massive die-off of cancer cells may result in the death of the patient.

5 A luteinizing hormone releasing factor (LHRF), sometimes generically referred to as gonadorelin, which causes luteinizing hormone, a pituitary gonadotropin, to be released from the pituitary, has been used for treating various tumors in U.S. Patent Nos. 4,002,738
10 and 4,071,622. Gonadorelin has also been used in the treatment of benign prostatic hyperplasia, a type of non-malignant but excess prostatic growth, in U.S. Patent No. 4,321,260. However, no indication is provided in these patents that direct application of any
15 gonadotropin may affect destruction of malignant neoplasms. In addition, release of LH from the pituitary is subject to a feedback control independent of the administered gonadotropin, so that how much, if any, LH released is not determinable merely from
20 knowledge of an administered dose. Moreover, LHRF in combination with other substances may act to increase chorionic gonadotropin secretion by direct action on a tumor cell, further compounding the uncertain effect of LHRF administration. Kellen, et al., AACR Abstracts,
25 23:235 (March 1982) (Abstract 928).

 In fact, Simon, et al., J.M.C.I., 70:839-845 (1983), indicates that dosages of gonadotropic and steroid hormones stimulate the growth of differentiated carcinomas. These hormones include human follicle-
30 stimulating hormone (FSH), HCG, human luteinizing hormone (LH), and cortisol. Thus Simon, et al., appears to support the idea that direct administration of gonadotropic or steroid hormones has a proliferative effect on malignant neoplasms.

35

- 9 -

Evidence for the suppression of the immune response against antigens of neoplastic cells is provided by Akiyama, et al., J. Immunol., 131:3085-3090 (1983), wherein responsiveness of a mixed culture of lymphocytes from cancer patients and healthy donors was suppressed by the introduction into the system of tumor cells from the cancer patients. This suggests that among the lymphocytes of the cancer patients were T_S cells specific for tumor-derived cells, inasmuch as the response of cultures containing only lymphocytes from healthy donors was not so suppressed.

Furthermore, antigen-specific T_S cells have been isolated from a mouse having a plasmacytoma, which cells inhibited the in vitro induction of a cytotoxic T-cell response against the tumor. Kolsch, Scand. J. Immunol., 19:387-393 (1984). According to Kolsch, T_S cells may be activated and may dominate T_H cells by high and low doses of antigen, but a critical, intermediate antigen dose which activates T_H cells at the same time as it activates the T_S cells, permits T_H cells to dominate. Thus, Kolsch indicates that there may be an antigen dose at which a delicate balance is reached where T_H cells are activated but at which T_S cells dominate the immune response.

In Loblay, et al., Aust. J. Exp. Biol. Med. Sci., 62:11-25 (1984), it is indicated that the suppression produced by T_S cells in animals which have been exposed to an antigen is enhanced by a subsequent administration of a sufficiently large dose of antigen. Perhaps it is not so surprising, therefore, that attempts to induce contrasuppression have been aimed at supplying contrasuppressor cells, or substances therefrom, rather than by direct induction of contrasuppression. See, Green, "Contrasuppression: Its

- 10 -

Role in Immunoregulation", in The Potential Role of T-Cells In Cancer Therapy, Fefer, et al., eds., Raven Press, New York (1982); and Green, et al., Ann. Rev. Immunol., 1:439-463 (1983).

5 The methods and compositions disclosed in this application utilize unusually low levels of ingredients which yield surprising and unexpected results given the low levels actually employed. Applicants note however that a recent study, Reilly, D.T., et al., Lancet, II, 10 881-886 (1986) tested whether homeopathic potencies are merely placebos in a randomized, double-blind, placebo-controlled trial. Homeopathy involves administering a greatly attenuated preparation of an agent which closely mimics the patients symptoms. The results indicated 15 that homeopathically treated patients showed a significant reduction in patient and doctor assessed symptoms associated with active hay fever. Thus, no evidence emerged to support the idea that placebo action fully explains the positive clinical responses to 20 homeopathic drugs. The article does not disclose or suggest a treatment for AIDS.

 U.S. Patent No. 4,410,510, issued to Livingston-Wheeler on October 1983, uses choriogonadotropin-like material (see column 6, lines 25 34-7), i.e., material that cross-reacts with anti-HCG antibodies in a pregnancy test kit and RIA, to treat chickens for a virally-induced tumor. However, Livingston-Wheeler does not disclose the use of ECG (equine chorio gonadotropin) or HCG, the use of a lysate 30 of S. aureus as an immune enhancer, or that either or a combination of both should be used in a dose lower than that required to provoke a humoral immune response.

 Knecht, Chem. Abstracts, 92:88377m (1980); provides negative results for the use of a HCG beta-subunit coupled to tetanus toxin in a study in which 35 hamsters implanted with a human carcinoma were

- 11 -

treated. Thus, Knecht does not disclose the use of ECG, the use of a lysate of S. aureus as an immune enhancer, or that either ECG or HCG or a combination of either with a bacterial lysate should be used in a dose lower than that required to provoke a humoral immune response.

5 Melmed, Chem. Abstracts, 99:689a (1983); reports that HCG stimulates proliferation of Nb2 rat lymphoma cells in vitro, with no effect being observed for subunits of HCG. Thus, Melmed does not disclose the use of ECG or HCG in the treatment of AIDS, the use of a
10 lysate of S. aureus as an immune enhancer, or that either or a combination of both should be used in a dose lower than that required to provoke a humoral immune response.

15 Papademetriou, Chem. Abstracts, 96:15389 (1982); reports that injection of 500 IU of HCG for six days in vivo or exposure of isolated macrophages to > 100 IU/ml in vitro rendered peritoneal macrophages cytotoxic against MLB-2 leukemia cells. However,
20 Papademetriou does not disclose the use of ECG in the treatment of AIDS, the use of a lysate of S. aureus as an immune enhancer, or that either or a combination of both should be used in a dose lower than that required to provoke a humoral immune response.

25 Crockford and Burchiel U.S. Patent No. 4,323,546, as reported in Crockford, April 1982, Chem. Abstracts, 92:176610n (1980); U.S. Patent No. 4,311,688, Burchiel, January 1982 as reported in Chem. Abstracts, 95:86351m (1981), discloses only the use of anti-HCG
30 antibodies and not HCG in the detection of cancers. Neither Crockford nor Burchiel discloses the direct administration of ECG or HCG in the treatment of AIDS, the use of a lysate of S. aureus as an immune enhancer, or that either or a combination of both should be used
35 in a dose lower than that required to provoke a humoral immune response.

- 12 -

Fuji Zoki Seiyaku (Derwent Abstract No. 89190 of a Japanese application published 10/31/80) discloses the use of an immunopotentiator produced by destroying S. aureus cells in the treatment of malignant tumors.

5 However, Fuji Zoki Seiyaku does not disclose the use of ECG or HCG in the treatment of AIDS, or that a bacterial lysate or a combination of a lysate and HCG or ECG should be used in a dose lower than that required to provoke a humoral immune response.

10 Hlavayova, Chem. Abstracts, 100:96263v (1984), discloses that staphylotoxin-treated sarcoma cells exhibit decreased growth rates when transplanted into susceptible hosts. However, Hlavayova does not disclose the use of ECG or HCG in the treatment of AIDS,
15 or that either a bacterial lysate or a combination of a bacterial lysate and a chorionic gonadotropin should be used in a dose lower than that required to provoke a humoral immune response.

Cooper, Chem. Abstracts, 100:84075x (1984),
20 discloses that serum treated with fixed S. aureus and injected intraperitoneally into tumor-bearing mice increased mean survival time. However, Cooper does not disclose the use of ECG or HCG in the treatment of AIDS, the use of a lysate of S. aureus as an immune enhancer,
25 or that either or a combination of both should be used in a dose lower than that required to provoke a humoral immune response.

Liu, Chem. Abstracts, 101:70689j (1984), discloses that ex vivo immunoabsorption with
30 Staphylococcus protein A-based filters results in a response to therapy in most feline leukemia virus-infected cats tested. However, Liu does not disclose the use of ECG or HCG in the treatment of AIDS, the use

- 13 -

of a lysate of S. aureus as an immune enhancer, or that either or a combination of both should be used in a dose lower than that required to provoke a humoral immune response.

5 Liu, Chem. Abstracts, 101:228353q (1984),
discloses injection of purified S. aureus protein A into
cats infected with feline leukemia virus leading to a
loss in viremia and to a correction of cytological and
hematological abnormalities. However, Liu does not
10 disclose the use of ECG or HCG in the treatment of AIDS,
or that either a bacterial lysate or a combination of a
bacterial lysate and a chorionic gonadotropin should be
used in a dose lower than that required to provoke a
humoral immune response.

15 Cohen, Chem. Abstracts, 101:65664t (1984),
discloses the treatment of venereal tumor-bearing dogs
and guinea pigs with Staphylococcus aureus protein A
injection and reports no regression of the tumors. Thus
Cohen does not disclose the use of ECG or HCG in the
20 treatment of AIDS, the successful use of a lysate of S.
aureus as an immune enhancer, or that either or a
combination of both should be used in a dose lower than
that required to provoke a humoral immune response.

 Langcone, Chem. Abstracts, 101:88606 (1984),
25 discloses that intact S. aureus cell wall and even
relatively high doses of Sepharose™ are active in
generating complement. However, Langcone does not
disclose the use of ECG or HCG in the treatment of AIDS,
the use of a lysate of S. aureus as an immune enhancer,
30 or that either or a combination of both should be used
in a dose lower than that required to provoke a humoral
immune response.

 Balint, Chem. Abstracts, 100:839365 (1984),
discloses that perfusion of sera from normal and breast
35 adenocarcinoma-bearing humans or dogs through
immobilized staphylococcal protein A produces eluates

- 14 -

which are tumoricidal and toxic upon reinfusion into the subject. However, Balint does not disclose the use of ECG or HCG in the treatment of AIDS, or that a bacterial lysate or a combination of a bacterial lysate and a chorionic gonadotropin should be used in a dose lower than that required to provoke a humoral immune response.

5 Chugai, Chem. Abstracts, 101:235588r (1984), discloses an anti-leukemic activity in mice of an isolate of S. aureus. However, Chugai does not disclose the use of ECG or HCG in the treatment of AIDS, or that either a bacterial lysate or a combination of a bacterial lysate and a chorionic gonadotropin should be used in a dose lower than that required to provoke a humoral immune response.

15 Mitsui, Chem. Abstracts, 101:17331k (1984), discloses that heat denatured DNA isolated from S. aureus inhibits neoplasms. However, Mitsui does not disclose the use of ECG or HCG in the treatment of AIDS, or that a bacterial lysate or a combination of a bacterial lysate and a chorionic gonadotropin should be used in a dose lower than that required to provoke a humoral immune response.

20 Miyakoshi, Chem. Abstract, 96:671278, (1982), reports Staphage lysate to be a useful mitogen for the in vitro study of cell-mediated immunity. However, Miyakoshi does not disclose the use of ECG or HCG in the treatment of AIDS, the use of a lysate of S. aureus as an immune enhancer, or that either or a combination of both should be used in a dose lower than that required to provoke a humoral immune response.

- 15 -

SUMMARY OF THE INVENTION

A method according to the present invention for alleviating symptoms of acquired immune deficiency syndrome in a disease victim comprises the steps of administering to the disease victim a member selected from the group consisting of characteristic substances of diseased cells of the acquired immune deficiency syndrome victim and effective fragments and effective derivatives thereof, in a pharmaceutically effective amount which is less than the lowest amount necessary to provoke a humoral immune response, as exemplified by the determination of a positive wheal upon subcutaneous injection. Illustrative of such a method is the administration of a composition including human chorionic gonadotropin (HCG), a lysate of S. aureus, influenza virus vaccine, and fractionated inactivated HIV virus.

A composition according to the present invention for alleviating symptoms of acquired immune deficiency syndrome in a disease victim comprises a member selected from the group consisting of characteristic substances of diseased cells of the acquired immune deficiency syndrome victim and effective fragments and effective derivatives thereof, in a pharmaceutically effective amount which is less than the lowest amount of the substance necessary to induce a humoral immune response. This composition also comprises an immune enhancer, such as BCG mycobacteria, Corynebacterium parvum, and levamisole, in an amount less than the lowest amount of the substance necessary to provoke a humoral immune response, as exemplified by the determination of a positive wheal upon subcutaneous injection. Illustrative of such a composition are compositions including HCG, a lysate of S. aureus, such as Staphage Lysate™, an influenza virus vaccine, such as

- 16 -

Fluogen™, and fractionated inactivated HIV virus. This composition is referred to below as Solution I.

Solution II is similar to Solution I and contains the same components with the exception that fractionated
5 inactivated HTLV-III virus is omitted and replaced with peptide T of HIV.

DESCRIPTION OF THE PREFERRED EMBODIMENT

10 In a method according to the present invention, a substance characteristic of AIDS is administered to a patient afflicted with AIDS in an amount which is believed to be less than the lowest amount necessary to provoke a humoral immune response
15 (that is, to begin production of antibody). This dosage is administered daily until disappearance of the symptoms of the disease, and may be administered longer without harm if so desired. The symptoms alleviated include fever, night sweats, malaise/fatigue, enlarged
20 nodes, weight loss, diarrhea and opportunistic infections.

In order to identify a dose lower than that required to provoke a humoral immune response, a wheal produced upon subcutaneous injection of the therapeutic
25 material is evaluated according to the procedure set forth in Moore, Clinical Medicine, 81:16-19 (1974), wherein such evaluation is employed to identify a dosage of vaccine useful in the eradication of the symptoms of influenza. Upon subcutaneous injection, a wheal may be
30 determined to be positive ten minutes after injection as blanched, hard, raised and discoid (regular, sharply demarcated edges, as though a disc has been cemented to the skin). A negative wheal, indicative of a dose below that necessary to provoke an immune response, is so
35 absorbed at the end of ten minutes that it is softer and

- 17 -

flatter than at injection, may have an irregular or ragged edge, and has grown less than an average of two millimeters in diameter from its original size.

Although a preferred dosage of 2 International Units (IU) was initially determined by skin tests of the horse of Example 1, the Examples below indicate that successful therapy may often be achieved by administering a dose at an initial level of 2 IU without an initial dosage level determination. A dose of 2 IU appeared to be low enough for any animal or human tested, even without first determining optimum dose by a skin test. However, it is believed that determination of a proper dosage, as exemplified above or otherwise, may be used by those skilled in the art to refine the method according to the present invention.

To complement the activity of the chorionic gonadotropin, and to simultaneously guard against a toxic reaction induced by a rapid sloughing of necrotic tissue analogous to a Herxheimer-type reaction, a bacterial lysate was added to each treatment vial as a broad-spectrum stimulator of cell-mediated immunity, i.e., as an immune enhancer. No species specificity of response was observed, to the extent that a human cancer patient has responded to either of equine chorionic gonadotropin (ECG) or HCG, and that other animals of the examples have also responded favorably to treatment with either ECG or HCG.

AIDS patients have been reported as exhibiting a marked reduction in the ratio of T_H to T_S cells. See, Cohen, British Journal of Hospital Medicine, 31:250-259 (1984). It has been reported that the virus thought to cause AIDS is a type of human T-cell leukemia-lymphoma virus (HTLV) known as HTLV-III virus and that this virus is related to the virus which causes feline and bovine leukemia. Franklin, Science News, 126:269 (1984). Feline and bovine leukemia viruses are known to be

- 18 -

antigenically similar. Morgan, et al., J. Virol., 46:177-186 (1983). Accordingly, the discovery by the present inventor that a dose of HCG which is lower than that required to provoke a humoral immune response may be effective in the alleviation of the symptoms of feline leukemia and of bovine leukemia, indicates the potential effectiveness of an analogous form of treatment in the alleviation of the symptoms of AIDS as well.

Furthermore, feline leukemia virus (FLV) and HTLV are both retroviruses (also known as Type C viruses, RNA tumor viruses, or leukemia viruses). Manzani, et al., Surv. Immunol. Res., 1:122-125 (1982). A retrovirus may be transmitted as an infectious particle containing viral genes encoded in the form of ribonucleic acid (RNA). Within an infected cell this RNA is encoded into deoxyribonucleic acid (DNA) by a viral enzyme called reverse transcriptase. The DNA-encoded viral genes are thereafter integrated with and replicated, transcribed and translated along with the DNA-encoded genetic material of the infected cell. Lewin, Chapter 13 in Genes, John Wiley and Sons, New York (1983). Such retroviruses generally produce steady state infections where viral progeny are continually extruded by budding from the surfaces of host cells. Thus, steady state viruses exhibit the clinical criteria for the induction of tolerance in that there is a high dose inoculum of viral antigen, the virus-specific antigen persists, and tumor-specific antigens are developed and persist. See Herberman, et al., supra.

Methods and compositions according to the present invention are shown in the examples below to be effective in the treatment of feline and bovine leukemia

- 19 -

among other neoplastic diseases. Similar methods and compositions according to the present invention are effective in the treatment of AIDS.

5 Examples 1, 2 and 3 below relate to the treatment of horses afflicted with two different types of malignant neoplasms.

Examples 4 and 5 below relate to the treatment of cats diagnosed as having feline leukemia.

10 Example 6 below relates to the treatment of cows afflicted with bovine leukemia.

Examples 7 and 8 below relate to the treatment of dogs afflicted with two different types of malignant neoplasm.

15 Example 9 below relates to the treatment of human patients afflicted with malignant neoplasms.

Example 10 below relates to the treatment of human patients diagnosed as having AIDS or ARC (AIDS Related Complex).

20 EXAMPLE 1

A horse with mastocytoma was treated with 2 IU per day of gonadotropin only (i.e., without the bacterial lysate immune enhancer). The gonadotropin used was equine chorionic gonadotropin, supplied by the
25 W. A. Butler Company, or human chorionic gonadotropin, supplied by the Ayerst Corp. (as A.P.L. - human chorionic gonadotropin). In this example and in the examples which follow, a dosage of 2 IU per day of either equine chorionic gonadotropin (ECG) or HCG was
30 used.

The horse showed rapid and significant diminution of tumors before succumbing to an Herxheimer-type reaction. (No such adverse effect was seen in
35 other treated animals when an immune enhancer was co-administered).

- 20 -

EXAMPLE 2

Three horses with melanoma were successfully treated, to the point of the disappearance of symptoms, according to the procedure of Example 1 above, but with the addition of a bacterial lysate immune enhancer. After the symptoms disappeared, the three animals received no further treatment and exhibited no recurrence of symptoms.

A suitable bacterial lysate immune enhancer, such as S. aureus, for employment in this procedure is sold under the name Staphage Lysate™, available from Delmont Labs. Staphage Lysate™ is a bacteriologically-sterile staphylococcal vaccine containing components of Staphylococcus aureus and culture medium ingredients (sodium chloride and ultrafiltered beef heart infusion broth). The staphylococcal components are prepared by lysing parent cultures of S. aureus, serologic types II and III, with a polyvalent staphylococcus bacteriophage. Each milliliter contains 120-180 million colony-forming units (cfu) of S. aureus and 100-1000 million staphylococcus bacteriophage plaque-forming units (pfu).

All treatment trials contained 2 IU gonadotropin plus 0.1 cc Staphage Lysate™ in each 0.5 cc shot. Regardless of species, type of malignancy, or size of cancer, all animals received a once-daily subcutaneous injection of the admixture of chorionic gonadotropin and immune enhancer until the tumor or leukemia had disappeared. All animals were diagnosed as having cancer by a licensed veterinarian.

- 21 -

EXAMPLE 3

One horse with an undifferentiated carcinoma of the face was successfully treated according to the procedure of Example 2 to the point of the disappearance of symptoms. After disappearance of the symptoms, the horse received no further treatment and exhibited no recurrence of symptoms.

EXAMPLE 4

A double-blind test of treatment of cats diagnosed as being infected with feline leukemia virus was conducted by a licensed testing laboratory. Laboratory tests for feline leukemia were conducted by a licensed laboratory, and biopsy tissue from some cases was examined by a veterinary reference laboratory. In all cases animals were treated as above, with termination of treatment coinciding with disappearance of symptoms. In no cases was it necessary to resume therapy for a second round of treatment. No side effects have been observed.

A double blind evaluation of the efficacy of daily doses of the combination of gonadotropin (2 units per dose) and Staphage Lysate™ (0.1 cc per dose) in cats with advanced leukemia was conducted under the supervision of, and the personnel for, TechAmerica, Inc. at their facility in Fort Collins, Colorado. Eight cats received treatment with the test material, while four received placebo (phenolated saline) daily injections. The results are indicated in Table 1 below.

30

35

- 22 -

TABLE 1RESULTS OF ADMINISTRATION OF HCG & SPL
TO CATS WITH ADVANCED FELINE LEUKEMIAANIMALS RECEIVING ADMIXTURE

5

<u>Cat Number</u>	<u>Survival (days)</u>	<u>Viremia</u>	<u>Tumor Mass</u>
2	16	Decreased	No change
3	42	Ceased	Reduced to Normal
10 7	4	No Test	No Test
11	19	Slight Decrease	No change
15	10	No Change	Slight Decrease
15 21	51	No Change	Reduced to Normal
23	51	Decreased	Reduced to Normal
24	Euthanized at 40	No Change	Reduced to Normal

ANIMALS RECEIVING PLACEBO

20

<u>Cat Number</u>	<u>Survival (days)</u>	<u>Viremia</u>	<u>Tumor Mass</u>
4	1	No Test	No Test
25 5	Euthanized at 10	No Change	No Change
16	6	No Test	No Change
22	6	No Test	No Test

30 All animals receiving a placebo died within 7 days. Some treated animals were still alive after six weeks, and were receiving no further treatment. Of special interest was the observation that several treated cats were not only asymptomatic, but also non-

- 23 -

viremic. In any event, survival was prolonged and/or symptoms were alleviated for 6 (cats numbered 2, 3, 11, 21, 23 and 24) of 8 treated animals, as compared to the animals receiving a placebo (cats numbered 4, 5 16 and 22 received a placebo).

Cat number 4 died one day after the start of the test. Cat number 4 was not necropsied. Cat number 5 showed no significant change in viremia. Tumor size remained constant. The cat was euthanized on day 10 of the test. At necropsy, the cat was observed to be moribund, thin, blind and anemic. Tumors were located on the tongue, and eyes, and in the pleural, perirenal and peritoneal cavities. Cat number 16 died six days after initial treatment. Upon necropsy, small metastatic tumors were observed in the lungs, and large tumors were observed in the omentum. Cat number 22 died six days after initial treatment. Upon necropsy, metastatic tumors were found in the lung, in the liver and in the omentum. The cause of death was renal hemorrhage into the retroperitoneal sublumbar region.

Cats numbered 2, 3, 7, 11, 15, 21, 23 and 24 received the experimental treatment.

In cat number 2, viremia decreased but the tumor remained the same size. Cat number 2 died 16 days after the start of the test. At necropsy, a tumor was found which was open and which had drained. General lymph node enlargement, an enlarged liver, and a small tumor in the apex of the heart were also noted.

In cat number 3, viremia decreased to negative. The tumor decreased in size back to a normal condition. The cat was normal in appearance during the test.

- 24 -

Cat number 7 died four days after initial treatment. No necropsy was performed.

Cat number 11 exhibited a slight decrease in viremia. Tumor size remained the same. Cat number 11
5 died 19 days after initial treatment. Upon necropsy, tumors were found throughout the body cavity.

Cat number 15 showed no significant decrease in viremia. No change in the tumor was observed. The cat died 10 days after initial treatment. At necropsy,
10 the cat was observed to be emaciated, and tumors were found in the lungs, mediastinum, pericardia, pleura and illiac lymph nodes.

In cat number 21 the viremia was constant. The cat appeared normal. Upon necropsy, an enlarged
15 thymus and enlarged mesenteric lymph nodes were observed.

In cat number 23, viremia decreased through the course of the test. Cat number 23 remained normal throughout the duration of the test.

20 In cat number 24, viremia remained constant. The cat appeared normal throughout the duration of the test. Upon necropsy, an enlarged thymus was observed, but the cat was otherwise normal.

25 EXAMPLE 5

Several dozen cats have been successfully treated for feline leukemia according to the procedure of Example 2 above by veterinarians in Ohio, Pennsylvania and North Carolina. Based upon the
30 reported observations of the veterinarians, at least 80% of the treated cats have returned to normal health after termination of therapy. For example, one cat exhibited little strength and its body weight was reduced from 13 pounds to 6 pounds. After ten days of therapy, the cat
35 was mobile and active, and its weight had increased to ten pounds.

- 25 -

EXAMPLE 6

Twenty cases of bovine leukemia were treated according to the procedure of Example 2 above, with complete remission of symptoms for as long as 13 months. Milk production of 17 cows was both restored and enhanced. Only three failures occurred, and in each case the cow had been moribund for several days before initiation of therapy. Laboratory tests for bovine leukemia were conducted by a licensed laboratory, and biopsy tissue from some cases was examined by a veterinary reference laboratory.

EXAMPLE 7

A squamous cell carcinoma on the jaw of a six-month-old pup was treated according to the procedure of Example 2 above. In spite of a "poor prognosis" from the veterinary reference laboratory examining the biopsy tissue, the dog entirely healed, as evidenced by sequential X-ray records.

A squamous cell carcinoma on the shoulder of a 12-year-old dog was treated according to the procedure of Example 2 above. After two days the dog could walk for extended periods, ate well, and the tumor became warm to the touch. Noticeable tumor shrinkage was observed after five days. After two weeks, the tumor was nearly resolved.

EXAMPLE 8

An anal tumor growing daily and laterally displacing the tail of a 13-year-old dog was treated according to the procedure of Example 2 above. The photographic record showed daily decrease in tumor size beginning on day three. The tumor resolved. The dog later died for unknown reasons. No necropsy was performed.

- 26 -

EXAMPLE 9

A limited number of human patients have been treated for cancers diagnosed as terminal, including melanoma and cancers of the colon, breast, liver, pancreas and lung. The patients were treated according to the procedure of Example 2 above, except that some patients received 0.2 cc of immune enhancer per dose rather than 0.1 cc per dose.

Of 9 patients treated at one location within a period of almost three years, all lived longer than the expected survival time initially indicated by their treating physicians. Patients began treatment with an expected survival of one month or less. As of August 1987, five of the nine patients had died. Two of the patients who died had discontinued treatment according to the present invention two months before death. Of the original nine patients, four survived more than 18 months, and, six survived 12 months since beginning treatment.

All nine patients practiced the method according to the present invention as a last resort, and all but the five patients who died, had had some form of radiation or chemotherapy prior to beginning therapy according to the present invention. All nine patients had diagnosed metastases indicative of an advanced disease state. No side effects were observed.

It is not clear, however, how regularly all patients administered the composition according to the present invention. For example, some surviving patients have decreased treatment to once or twice per week without a reduction in overall well-being. Of the four patients still surviving, one has entirely discontinued treatment with no sign of disease; two have continued

- 27 -

treatment and have been disease-free for six months; and one has continued treatment and has a residual enlarged lymphoma node.

5 Sporadic treatment at other locations was not as successful, so that overall, about half of the treated patients are still surviving, while the other half have died. Due to the lack of autopsy data, it is not clear whether all of the deaths of treated patients may properly be attributed to cancer or to other causes.

10 Patients who had not received maximum chemotherapy and radiation responded most positively to the composition and method of the present invention. This suggests that the therapeutic agent of the present invention involves, at least in part, immune
15 manipulation, and that the cells comprising the immune response are compromised in patients receiving traditional anti-cancer therapy.

EXAMPLE 10

20 Due to the complexity of the pathogenesis of AIDS and ARC (AIDS Related Complex), it is postulated that it is useful for a therapeutic agent to simultaneously i) inhibit replication of the putative
caustive agent (HIV); ii) restore immune function in a
25 controlled fashion to heal the compromised immune system without inducing auto-immunity or some other hyperimmune dysfunction; iii) inhibit secondary viral infections such as those caused by the cytomegalovirus or Epstein
Barr virus; and iv) decrease the likelihood of
30 complications from malignancies such as lymphomas or Kaposi's sarcomas which commonly further compromise the condition of the AIDS patient.

An admixture of substances was prepared with the following components. Chorionic gonadotropin was
35 shown in the above examples, when used in low concentrations, to be extremely promising in treating a

- 28 -

variety of malignant states in man and animals. It may be the case that chorionic gonadotropin alters the electrical charge on transformed cells thereby decreasing their relative negativity and thus rendering them more vulnerable to phagocytic and immune action. A bacterial lysate immune enhancer such as S. aureus, i.e., Staphage™ Lysate, was used in conjunction with chorionic gonadotropin to enhance immune activity and to prevent the Herxheimer-type reactions that have been observed in animals treated with HCG alone. An influenza virus vaccine, such as Fluogen™, when used in doses as low as one five hundredth the normal vaccine dose, is effective in controlling a variety of Herpes infections. An influenza vaccine, appears to be active at a level of immune responsiveness considerably different from that stimulated by vaccination, Miller, J.B., et al., J. of Med. Assoc. of Alabama, 41:493 (1972) and Miller, J.B., Anal. of Allergy, 42:295 (1979), and it was surmised that a low level of the AIDS agent, or its components, might perform the same way for the AIDS patient, i.e., stimulate the interference of virus infection and/or replication even in an immunologically compromised host. Accordingly, HIV virus fractions are also a component of the admixture.

An aqueous solution according to the present invention, (hereinafter solution I) for subcutaneous injection, containing the following combined components was prepared:

1. Human Chorionic Gonadotropin (APL) (Ayerst Labs, Division Home Products Corp., 685 Third Avenue, New York, NY) diluted in phenolated saline such that each 0.5 cc dose contains 2.0 International Units.

- 29 -

2. Staphage Phage Lysate (SPL) (Delmont Laboratories, Inc., P.O. Box AA, Swathmore, PA), formulated to contain 120-180 million colony-forming units of S. aureus and 100-1000 million Staphylococcus bacteriophage plaque-forming units (Seriological Types I and III, with a polyvalent staphylococcus bacteriophage) - Each 0.5 cc dose contains 0.2 cc of this product.
3. 1:25 dilution of an influenza virus vaccine such as Fluogen™ (Parke-Davis a Division of Warner-Lambert Co., 201 Tabor Road, Morris Plains, NJ) influenza virus vaccine, formulated to contain no less than 45 µg of hemagglutinin antigen per 0.5 mL dose - Each 0.5 cc dose contains 0.05 cc of this dilution.
4. Fractionated inactivated HTLV-III virus (Organon Teknika Corp., 800 Capitol Drive, Durham, NC) - Diluted such that each 0.5 cc dose contains the equivalent of approximately four virus particles.
5. Phenolated Saline (Allergy Laboratories, Inc., 1005 SW Second Street, Oklahoma City, OK) - Normal saline with 0.4% phenol, used as supplied to bring up to a 0.5 cc dose.

Because Solution I consists of a combination of commercially available products, the preparation of the admixture to be evaluated consists solely of diluting the respective components to their appropriate

- 30 -

concentrations and combining these dilutions into a final dosage for evaluation. Phenolated saline is used as a diluent throughout. The various components (except for the HTLV-III fraction) had been used safely alone or in various combinations for diseases other than AIDS. Further animal testing of one combination of two of the components of Solution I had proven significantly promising for the successful treatment of malignancies in animals as indicated in the above examples.

A pilot study of the use of the above aqueous solutions for the treatment of AIDS/ARC in five patients was conducted. Patients were treated with the Solution I admixture for 30 consecutive days, receiving 0.5 cc of the medicine subcutaneously each day. This period was followed by an equal period (30 days) without treatment, after which therapy was re-initiated and continued for an additional 13 months. The clinical results are summarized in Table 2 below. Table 3 lists the results of blood tests on these patients and Table 4 give the Natural Killer (NK) cell activity of these patients. Patients numbers 2, 4, and 5 received a modified version, referred to as Solution II, of the Solution I admixture one month prior to day 450, 409, and 444, respectively. This Solution II contained the same components as Solution I, listed on page 29, with the exception of component 4: the fractionated inactivated HTLV-III virus was omitted and replaced with "peptide T", an octapeptide (Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr), corresponding to an amino acid sequence extant in HIV envelope glycoprotein gp 120, and which has been described in Pert, et al., Proc. Nat'l. Acad. Sci., 83:9254-9258 (1986). Peptide T was purchased from Peninsula Laboratories, Inc.; 611 Taylor Way; Belmont, CA 94002. The total dose of Solution II administered daily was 0.5 cc and was diluted to a concentration of one $\times 10^{-16}$ mg per 0.5 cc dose.

- 31 -

TABLE 2CLINICAL RESULTS OF ADMINISTRATION
OF SOLUTION I

5	<u>Description</u>	<u>Patient Number</u>				
		1	2	3	4	5
	Age	40	30	34	30	28
	Race	C	C	C	C	C
10	Risk Group	HSex	HSex	HSex	BiSex	BiSex
	Drug User	Nitrites	Nitrites	Nitrites	No	Varied
	Clinical Group	ARC	ARC	ARC	ARC	ARC-AIDS
15	<u>Symptoms(Initial)</u>					
	Fever	+	-	-	+	-
	Night Sweats	-	-	-	+	+
20	Malaise/fatigue	+	-	+	+	+
	Enlarged Nodes	+	+	+	+	+
	Weight Loss	±	-	-	±	+
	Diarrhea	+	-	-	-	±
25	Opportunistic Infections	-	-	-	Candida HSV-1	Bacterial Pneumonia

30

35

- 32 -

TABLE 2 - cont'd

Signs and Symptoms During First Ninety Days of Trial
(30 days on medication, 30 days off, 30 days on)

5 Patient #1 - Delayed hypersensitivity reaction at
injection site; GI gas, sinusitis and
diarrhea all more pronounced when off
medication; sever tonsilitis when off
medication.

10 Patient #2 - Some hypersensitivity at injection site;
anxiety level increased during first course
of therapy, then lessened; allergic
sinusitis and rhinitis more pronounced off
15 Solution I; fatigue increased off Solution I.

Patient #3 - Delayed reaction at injection sites; rapid
resolution of HSV-II on Solution I;
increased malaise and slower HSV-II resolu-
20 tion when off medication.

Patient #4 - Similar hypersensitivity pattern; calmer on
medication; night sweats and node size and
tenderness increased when off medication;
25 leukoplakia when off medication.

Patient #5 - No hypersensitivity response on any
injection; rapid decrease of night sweats
and diarrhea with Solution I; feeling of
30 "queasiness" when first on injections -
followed injection by 10-15 minutes and
lasted 1-2 hours; increased energy when on
medication.

35

- 33 -

TABLE 2 - cont'dClinical Status Approximately
Ten Months After Initiation of Treatment

5

Patient #1 - Has gained weight, no opportunistic infections, good energy, no nodes.

10

Patient #2 - Continues well, has gained weight, no infections, no nodes.

15

Patient #3 - Continues well with respect to HSV-II, good energy, maintains weight after gaining slightly since start, nodes low.

20

Patient #4 - Former sense of nervousness and uneasiness has lessened markedly, weight steady, energy good, no night sweats.

25

30

35

Patient #5 - Continues to gain weight slowly, no nodes or sweats, no infections, good energy.

TABLE 3

Blood Parameters of Patients

Patient #1	Baseline	Treatment 7 Days	Treatment 28 Days	Off 30 Days	Treatment 14 Days	Treatment 28 Days	Treatment 365 Days
WBC	7700	7500	6200	5900	5000	4700	4900
Lymphs	3400	3300	2300	2800	2400	2200	2100
Segs	48%	45	55	44	45	50	41
Bands	1%	3	2	--	3	--	
Lymph	44%	44	37	47	48	46	
Monos	7%	7	3	8	4	3	
Eos	--	1	3	1	--	1	
OKT3	79%/2685	75/2479	74/1702	75/2100	75/1800	79/1738	79/1559
OKT11	91%/3094	93/3069	91/2093	93/2604	90/2160	92/2024	89/1869
OKT4	15%/510	13/429	16/368	12/336	16/384	15/330	17/336
OKT8	63%/2142	60/1980	59/1357	61/1708	62/1488	63/1386	65/1365
Ratio 4:8	0.2	0.2	0.27	0.2	0.26	0.2	
Leu16	2%/68	1/33	2/46	3/84	2/48	3/66	3/63

TABLE 3 (continued)

Patient #2

	Baseline	Treatment 7 Days	Treatment 28 Days	Off 30 Days	Treatment 14 Days	Treatment 28 Days	Treatment 375 Days	Treatment 385 Days
WBC	4700	4400	4100	3600	3200	3900	3500	4700
Lymph	2773	2400	1800	2300	1300	2300	2700	2800
Segs	27%	41	50	33	48	32	21	--
Bands	2%	2	2	--	5	1	--	--
Lymphs	59%	54	43	64	42	59	--	--
Monos	9%	3	1	3	3	8	--	--
Eos	3%	--	4	--	2	--	--	--
OKT ₃	89.7%/2152	90/2160	90/1620	89/2047	92/1196	90/2070	87/2349	91/2548
OKT ₁₁	95.1%/2280	96/2304	87/1566	84/1932	94/1222	85/1955	83/2241	92/2576
OKT ₄	15.7%/377	15/360	16/288	16/368	16/208	15/345	11/297	10/280
OKT ₈	65.7%/1577	68/1632	68/1224	65/1495	64/832	64/1472	63/1700	71/1988
Ratio 4:8	0.24	0.22	0.24	0.25	0.3	0.2	--	--
Leu16	3.7%	2/48	3/54	2/46	3/39	24/552	5/135	4.4/123

TABLE 3 (continued)

Patient #3

	Baseline	Treatment 7 Days	Treatment 28 Days	Off 30 Days	Treatment 14 Days	Treatment 28 Days	Treatment 348 Days
WBC	5200	5200	5500	4900	4400	4600	6300
Lymph	1400	1456	1900	2400	1000	1200	2300
Segs	61%	58	48	44	66	66	36
Bands	4%	--	6	1	1	1	--
Lymph	24%	28	34	48	22	25	--
Monos	8%	13	7	6	7	4	--
Eos	--	1%	5	1	4	4	--
OKT ₃	82%/1148	85/-	81/1539	77/1848	84/840	79/948	80/1840
OKT ₁₁	86%/1204	86.5/-	88/1672	80/1920	90/900	84/1008	80/1840
OKT ₄	33%/462	26.2/-	32/608	35/840	34/340	33/396	30/690
OKT ₈	44%/616	43/-	53/1007	45/1080	49/490	44/528	49/1127
Ratio 4:8	0.8	0.61	0.8	0.7	0.8	0.7	--
Leu16	8%/112	8/-	6/114	5/120	6/60	4/48	10/230

TABLE 3 (continued)

Patient #4	Baseline	Treatment 7 Days	Treatment 28 Days	Off 30 Days	Treatment 14 Days	Treatment* 28 Days	Treatment 334 Days	Treatment 344 Days
WBC	--	6200	6200	6000	5700	--	4000	3900
Lymph	--	1300	1800	1700	2000	--	1100	1200
Segs	--	67%	62	60	55	--	28	--
Bands	--	3%	1	1	1	--	--	--
Lymph	--	21%	29	29	35	--	--	--
Mono	--	8%	4	9	5	--	--	--
Eos	--	--	4%	1	3	--	--	--
OKT3	88%	84/1092	84/1512	89/1513	87/1740	--	82/918	81/972
OKT11	91%	82/1066	80/1440	92/1564	86/1720	--	83/930	87/1044
OKT4	26%	26/338	23/414	22/374	23/460	--	19/213	18/216
OKT8	61%	51/663	56/1008	57/969	56/1120	--	60/672	60/720
Ratio 4:8	0.4	0.5	0.4	0.4	0.4	--	--	--
Leu16	5%	5/65	3/54	4/68	2/40	--	6/67	5.2/62

* Data not determined.

- 38 -

TABLE 3 (continued)

Patient #5

	Baseline	Treatment 7 Days	Treatment 28 Days	Off 30 Days
WBC	--	3300	3300	3700
Lymph	--	2000	1400	1600
Segs	--	28%	30	46
Bands	--	--	4%	--
Monos	--	8%	21	11
Eos	--	3%	2	--
OKT ₃	83%	84/1680	80/1120	83/1328
OKT ₁₁	67%	69/1380	61/854	72/1152
OKT ₄	21%	25/500	24/336	20/320
OKT ₈	61%	54/1050	57/798	62/992
Ratio 4:8	0.3	0.2	0.4	0.3
Leu16	4%	2/40	5/70	5/80

Table 4

NATURAL KILLER CELL ACTIVITY OF
PATIENTS UNDER TREATMENT

PATIENT	DAYS ELAPSED	NK ACTIVITY	
		50/1	25/1
(1)	0	21%	8%
	10	54%	34%
	21	31%	21%
	38	22%	13%
	65	28%	13%
	94	19%	8.7%
	170	70%	-
	430	6.4%	1.6%
(2)	0	19%	12%
	10	14%	9%
	31	5.4%	2.2%
	59	24%	9.4%
	73	4.2%	1.9%
	85	8.3%	5.8%
	113	32%	18%
	146	22%	16%
	409	6.6%	0.0%
	440	6.8%	1.5%
	*450	93.0%	15%
(3)	0	17%	-
	4	26%	12%
	26	16%	-
	63	42%	24%
	77	8.9%	3.4%
	89	31.7%	12.8%
	117	35%	21%
	150	50%	32%
	413	17.5%	1.9%
(4)	0	17%	-
	7	17%	-
	34	22%	12%
	63	3.8%	2.1%
	75	24%	11%
	90	16%	7%
	105	8%	8%
	368	3.0%	0.0%
	399	11.9%	6.8%
	*409	60%	58%
(5)	0	5%	2%
	14	4%	1%
	16	6.5%	3.4%
	46	13%	7%
	59	4.4%	2.3%
	74	8.1%	4.2%
	133	28%	18%
	*444	34.6%	29%

* See text for description of change in treatment from Solution I to Solution II.

- 40 -

The results indicated in Tables 2, 3, and 4 demonstrate that these patients were effectively treated and that their symptoms of AIDS/ARC are effectively under control as exemplified by a decreased incidence of night sweats, weight loss, lethargy, opportunistic infections and enlarged lymph nodes. Laboratory parameters show a slow return towards normal of NK activity, T_4 numbers, and $T_4:T_8$ ratios. Furthermore, all patients are able now to work full time or to split time between work and college classes.

The effectiveness of treatment of malignant neoplasms, feline leukemia, and AIDS with gonadotropins may be explained in a number of ways. The rapidity of the response achieved according to the present invention, even with administration of HCG alone as in Example 3, suggests that the present invention is not operating merely by the initiation of a humoral immune response. One explanation is that the low dosage of gonadotropin stimulates a contrasuppression reaction by tipping the balance of the T_H/T_S ratio in favor of activation of T_H cells; and that this leads to the release of a pre-existing immune response (including a CMI response) against the disease. Another explanation may be that the gonadotropin acts in a negative feedback mechanism to turn off production of gonadotropin-like molecules by the malignant cells, leading in turn to a change in the surface charge from the negative charge associated with gonadotropin-like molecules to a more positive charge which facilitates ingestion by macrophages, or leading to exposure of otherwise hidden tumor antigens. However, it is not intended that the present invention be limited to any explanation.

- 41 -

While the present invention has been described in terms of specific methods and compositions, it is understood that variations and modifications will occur to those skilled in the art upon consideration of the present invention.

For example, it is envisioned that various derivatives and fragments of the recited human chorionic gonadotropin and other tumor- or viral-specific antigens will be effective according to the present invention. In addition, although the preferred route of administration is by subcutaneous injection, it is not intended to preclude intramuscular, intraperitoneal, or intravenous injection, intranasal administration, or any other effective route of administration from being included within the scope of the present invention.

Also, inasmuch as other tumor markers, such as carcinoembryonic antigen, alpha-fetoprotein and tissue polypeptide antigen, are classified with HCG in relation to appearance in association with malignant neoplasms and are, therefore, likely to be similarly effective, it is intended that these substances be included within the scope of the present invention as well.

Furthermore, human chorionic gonadotropin, follicle-stimulating hormone, luteinizing hormone and thyroid-stimulating hormone are each glycoproteins composed of an α and a β subunit. The α subunit of HCG differs only slightly from an α subunit which is identical in each of FSH, LH and TSH. Although the significance of the subunit structure is yet to be determined, both α - and β -HCG have been associated with tumors. See Acevedo, et al., Infection and Immunity, 31:487-494 (1981). Accordingly, it is intended that these pituitary hormones be included within the scope of the present invention.

- 42 -

Still further, it is envisioned that immune enhancers other than lysates of S. aureus are believed to be effective. Such other immune enhancers include, for example, BCG mycobacteria, Corynebacterium parvum and levamisole. It is accordingly intended that these immune enhancers be included within the scope of the invention.

Additionally, influenza virus vaccines, other than an influenza virus vaccine such as Fluogen[™], are believed to be effective. Such other influenza vaccines include the components of the influenza virus vaccine: neuraminidase and hemagglutinin. It is accordingly intended that such influenza vaccines be included within the scope of the present invention.

In addition, although phenolated saline is described as the diluent used, other diluents such as water, normal saline, physiological saline or any other diluent suitable for administration by the intended route is included within the scope of the invention.

It is anticipated that effective fractionated inactivated fragments of other viruses, related to HIV virus, such as might be present in other retrovirus disease states, e.g., leukemia viruses, HTLV-I, HTLV-II and HTLV-IV viruses, are believed to be effective in alleviating symptoms of those viral disease states. Therefore, it is intended that these are included within the scope of the present invention.

It is contemplated that pharmaceutically effective fragments and effective derivatives of all of the foregoing suggested substances, including those synthesized by recombinant or chemical means by those skilled in the art, may be employed according to the present invention. For example, expression of gene products, i.e., proteins, protein fragments, and peptides have been described for HTLV-III [Chang, et al., Nature, 315:151 (1985); Chang, et al., Bio/Tech.,

- 43 -

3:905 (1985); Ratner, et al., Nature, 313:277 (1985); Crowl, et al., Cell, 41:979-986 (1985)]; for HTLV-III/LAV [Muesing, et al., Nature, 313:450 (1985);

5 Franchini, et al., PNAS, 83:5282-5285 (1986); Putney, et al., Science, 234:1392 (1986); and Kieny, et al., Bio/Tech, 4:790 (1986)]; and for ARV-2 (AIDS-associated retrovirus) [Luciw, et al., Nature, 312:760 (1984); and Sanchez-Pescador, et al., Science, 227:482 (1985)]. See
10 also, Hu, et al., Nature, 320:537 (1986); Chakrabarti, et al., Nature, 320:535 (1986); and Cabradilla, et al., Bio/Tech, 4:128 (1986). These effective fragments and derivatives are also intended to come within the scope of the invention as claimed.

15 Accordingly, it is intended in the appended claims to cover all such equivalent variations which come within the scope of the invention as claimed.

20

25

30

35

- 44 -

WHAT IS CLAIMED IS:

1. A method for alleviating symptoms of
5 acquired immune deficiency syndrome in a patient
afflicted with acquired immune deficiency syndrome or
acquired immune deficiency syndrome related complex
comprising the steps of:

administering to the afflicted patient a
10 member selected from the group consisting of
characteristic substances of diseased cells of the
acquired immune deficiency syndrome and effective
fragments and effective derivatives thereof in a
pharmaceutically effective amount which is less than the
15 lowest amount necessary to provoke a humoral immune
response in combination with the member, as exemplified
by the presence of a positive wheal upon subcutaneous
administration; and

co-administering an immune enhancer in a
20 pharmaceutically effective amount which is less than the
lowest amount of the substance necessary to induce a
humoral immune response in combination with the member,
as exemplified by the presence of a positive wheal upon
subcutaneous administration.

25

2. A method for alleviating symptoms of
acquired immune deficiency syndrome in a patient
afflicted with acquired immune deficiency syndrome or
acquired immune deficiency syndrome related complex
30 comprising the steps of:

administering to the afflicted patient a
member selected from the group consisting of
characteristic substances of diseased cells of the
acquired immune deficiency syndrome and effective
35 fragments and effective derivatives thereof in a
pharmaceutically effective amount which is less than the
lowest amount necessary to provoke a humoral immune

- 45 -

response in combination with the member, as exemplified by the presence of a positive wheal upon subcutaneous administration; and

5 co-administering a bacterial lysate in a pharmaceutically effective amount which is less than the lowest amount necessary to provoke a humoral immune response in combination with the member, as exemplified by the presence of a positive wheal upon subcutaneous
10 administration; and

co-administering influenza virus vaccine in a pharmaceutically effective amount which is less than the lowest amount necessary to provoke a humoral immune response in combination with the member, as exemplified
15 by the presence of a positive wheal upon subcutaneous administration; and

co-administering human chorionic gonadotropin in a pharmaceutically effective amount which is less than the lowest amount necessary to provoke a humoral
20 immune response in combination with the member, as exemplified by the presence of a positive wheal upon subcutaneous administration.

3. The method for alleviating symptoms of
25 acquired immune deficiency syndrome as recited in claim 2 wherein said bacterial lysate is a lysate of Staphylococcus aureus.

4. The method for alleviating symptoms of
30 acquired immune deficiency syndrome as recited in claim 2, wherein

said member is administered in a 0.5 cc dose;
said lysate of Staphylococcus aureus is
administered in a 0.5 cc dose;

35

- 46 -

said influenza virus vaccine is administered
in a 0.5 cc dose; and

said human chorionic gonadotropin is
5 administered in a 2 IU dose.

5. The method for alleviating symptoms of
acquired immune deficiency syndrome, as recited in claim
2, wherein said effective fragments comprise peptide T.

10

6. A composition for alleviating symptoms of
acquired immune deficiency syndrome in a patient
afflicted with acquired immune deficiency syndrome or
acquired immune deficiency syndrome related complex
15 comprising:

a member selected from the group consisting of
characteristic substances of diseased cells of the
acquired immune deficiency syndrome and effective
fragments and effective derivatives thereof in a
20 pharmaceutically effective amount which is less than the
lowest amount necessary to provoke a humoral immune
response in combination with the member, as exemplified
by the presence of a positive wheal upon subcutaneous
administration; and

25

an immune enhancer in a pharmaceutically
effective amount which is less than the lowest amount
necessary to provoke a humoral immune response in
combination with the member, as exemplified by the
presence of a positive wheal upon subcutaneous
30 administration.

35

7. A composition for alleviating symptoms of
acquired immune deficiency syndrome in a patient
afflicted with acquired immune deficiency syndrome or
acquired immune deficiency syndrome related complex
35 comprising:

- 47 -

a member selected from the group consisting of characteristic substances of diseased cells of the acquired immune deficiency syndrome and effective fragments and effective derivatives thereof in a pharmaceutically effective amount which is less than the lowest amount necessary to provoke a humoral immune response in combination with the member, as exemplified by the presence of a positive wheal upon subcutaneous administration; and

a bacterial lysate in a pharmaceutically effective amount which is less than the lowest amount necessary to provoke a humoral immune response in combination with the member, as exemplified by the presence of a positive wheal upon subcutaneous administration; and

influenza virus vaccine in a pharmaceutically effective amount which is less than the lowest amount necessary to provoke a humoral immune response in combination with the member, as exemplified by the presence of a positive wheal upon subcutaneous administration; and

human chorionic gonadotropin in a pharmaceutically effective amount which is less than the lowest amount necessary to provoke a humoral immune response in combination with the member, as exemplified by the presence of a positive wheal upon subcutaneous administration.

8. The composition for alleviating symptoms of acquired immune deficiency syndrome, as recited in claim 7, wherein said effective fragments comprise peptide T.

- 48 -

9. The composition for alleviating symptoms of acquired immune deficiency syndrome, as recited in claim 7, wherein said bacterial lysate is a lysate of Staphylococcus aureus.

10. The composition for alleviating symptoms of acquired immune deficiency syndrome, as recited in claim 7, comprising:

- 10 a 0.05 cc dose of said member;
- a 0.2 cc dose of said bacterial lysate;
- a 0.05 cc dose of said influenza virus vaccine; and
- 15 a 2.0 International Unit dose of said human chorionic gonadotropin.

20

25

30

35

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US88/02822

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC INT CL.: A61K 39/00; 45/05; 39/40 US. CL.: 424/88;85																							
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; border: 1px solid black; padding: 5px;">Classification System</td> <td style="border: 1px solid black; padding: 5px;">Classification Symbols</td> </tr> <tr> <td style="border: 1px solid black; padding: 5px;">U.S.</td> <td style="border: 1px solid black; padding: 5px;">424/88;85</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	U.S.	424/88;85																	
Classification System	Classification Symbols																						
U.S.	424/88;85																						
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border: 1px solid black; padding: 5px;">Category [*]</th> <th style="width: 70%; border: 1px solid black; padding: 5px;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 20%; border: 1px solid black; padding: 5px;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="border: 1px solid black; text-align: center; padding: 5px;">A</td> <td style="border: 1px solid black; padding: 5px;">US, A, 3,883,499 (TACHIBANA ET AL) 13 May 1975 (Abstract and columns 1-6).</td> <td style="border: 1px solid black; text-align: center; padding: 5px;">1-10</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; padding: 5px;">A</td> <td style="border: 1px solid black; padding: 5px;">US, A, 4,173,641 (KRASKA) 6 Nov. 1979 (Abstract and columns 1-16).</td> <td style="border: 1px solid black; text-align: center; padding: 5px;">1-10</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; padding: 5px;">A</td> <td style="border: 1px solid black; padding: 5px;">US, A, 4,395,394 (WOLFFE ET AL) 26 July 1983 (Abstract and columns 1-8).</td> <td style="border: 1px solid black; text-align: center; padding: 5px;">1-10</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; padding: 5px;">A</td> <td style="border: 1px solid black; padding: 5px;">US, A, 4,520,113 (GALLO ET AL) 28 May 1985 (Abstract and columns 1-8).</td> <td style="border: 1px solid black; text-align: center; padding: 5px;">1-10</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; padding: 5px;">A,P</td> <td style="border: 1px solid black; padding: 5px;">US, A, 4,692,332 (Mc MICHAEL) 8 September 1987 (Abstract and columns 1-14).</td> <td style="border: 1px solid black; text-align: center; padding: 5px;">1-10</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; padding: 5px;">A,P</td> <td style="border: 1px solid black; padding: 5px;">US, A, 4,708,818 (MONTAGNIER ET AL) 24 November 1988 (Abstract and columns 1-14).</td> <td style="border: 1px solid black; text-align: center; padding: 5px;">1-10</td> </tr> </table>			Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	A	US, A, 3,883,499 (TACHIBANA ET AL) 13 May 1975 (Abstract and columns 1-6).	1-10	A	US, A, 4,173,641 (KRASKA) 6 Nov. 1979 (Abstract and columns 1-16).	1-10	A	US, A, 4,395,394 (WOLFFE ET AL) 26 July 1983 (Abstract and columns 1-8).	1-10	A	US, A, 4,520,113 (GALLO ET AL) 28 May 1985 (Abstract and columns 1-8).	1-10	A,P	US, A, 4,692,332 (Mc MICHAEL) 8 September 1987 (Abstract and columns 1-14).	1-10	A,P	US, A, 4,708,818 (MONTAGNIER ET AL) 24 November 1988 (Abstract and columns 1-14).	1-10
Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³																					
A	US, A, 3,883,499 (TACHIBANA ET AL) 13 May 1975 (Abstract and columns 1-6).	1-10																					
A	US, A, 4,173,641 (KRASKA) 6 Nov. 1979 (Abstract and columns 1-16).	1-10																					
A	US, A, 4,395,394 (WOLFFE ET AL) 26 July 1983 (Abstract and columns 1-8).	1-10																					
A	US, A, 4,520,113 (GALLO ET AL) 28 May 1985 (Abstract and columns 1-8).	1-10																					
A,P	US, A, 4,692,332 (Mc MICHAEL) 8 September 1987 (Abstract and columns 1-14).	1-10																					
A,P	US, A, 4,708,818 (MONTAGNIER ET AL) 24 November 1988 (Abstract and columns 1-14).	1-10																					
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>[*] Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 50%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>																							
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border: 1px solid black; padding: 5px;"> Date of the Actual Completion of the International Search 04 October 1988 </td> <td style="width: 50%; border: 1px solid black; padding: 5px;"> Date of Mailing of this International Search Report 30 NOV 1988 </td> </tr> <tr> <td style="border: 1px solid black; padding: 5px;"> International Searching Authority ISA/US </td> <td style="border: 1px solid black; padding: 5px;"> Signature of Authorized Officer RONALD W. GRIFFIN </td> </tr> </table>			Date of the Actual Completion of the International Search 04 October 1988	Date of Mailing of this International Search Report 30 NOV 1988	International Searching Authority ISA/US	Signature of Authorized Officer RONALD W. GRIFFIN																	
Date of the Actual Completion of the International Search 04 October 1988	Date of Mailing of this International Search Report 30 NOV 1988																						
International Searching Authority ISA/US	Signature of Authorized Officer RONALD W. GRIFFIN																						

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

A,P	US, A, 4,732,864 (TOLMAN), , 22 March 1988 (Abstract and columns 1-20).	1-10
A	CABRADILLA, D.C., ET AL <u>Bio/Technology</u> , 4:128-133 (1986).	1-10

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____, because they relate to subject matter ¹² not required to be searched by this Authority, namely:
2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out ¹³, specifically:
3. ☐ Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No ¹⁸
A	CHAKRABARTI, S., ET AL., <u>Nature</u> 320:535-537 (1986).	1-10
A	CHANG, N.T., ET AL., <u>Nature</u> 315:151-154 (1985).	1-10
A	CHANG, T.W., ET AL., <u>Bio/Technology</u> 3:905-909 (1985).	1-10
A	COHEN, J., <u>British Journal of Hospital Medicine</u> , 31:250-259 (1984)	1-10
A	CROWL, R., ET AL., <u>Cell</u> , 41:979-986 (1985).	1-10
A	FRANCHINI, G., ET AL., <u>Proc. Nat'l. Acad. Sci. USA</u> , 83:5282-5285 (1986).	1-10
A	FRANKLIN, D., <u>Science News</u> , 126:261 (1984).	1-10
A	GERSHON, R.K., ET AL., <u>J. Exp. Med.</u> 153:1533-1546 (1981).	1-10
A	HU, S., ET AL., <u>Nature</u> , 320:537-540 (1986).	1-10
A	KIENY, M.P., ET AL., <u>Bio/Technology</u> 4:790-795 (1986).	1-10
A	KOLSCH, E., <u>Scand. J. Immunol.</u> , 19:387-393 (1984).	1-10
A	LUCIW, P.A., ET AL., <u>Nature</u> , 312:760-763 (1984).	1-10
A	MILLER, J.B., <u>Anal. of Allergy</u> 42:295-305 (1979).	1-10
A	MUESING, M.A., ET AL., <u>Nature</u> 313:450-458 (1985).	1-10
A	PUTNEY, S.D., ET AL., <u>Science</u> , 234: 1392-1395 (1986).	1-10
A	RATNER, L., ET AL., <u>Nature</u> , 313: 277-284 (1985).	1-10
A	SANCHEZ-PESCADOR, R., ET AL., <u>Science</u> , 227:484-492 (1985).	1-10